Another example about the link between VEGF and CCL2 is that the concurrent use of anti-VEGFA (bevacizumab) and anti-CCL2 therapy inhibits tumor angiogenesis and growth more effectively than treatments alone in CRCs with ETV5 high expression (57). This evidence concerns the gene CCL2 and neoplasm.